Compugen (CGEN)

Executive Summary

Compugen Ltd. is a clinical-stage cancer immunotherapy company leveraging its proprietary AI/ML-powered Unigen™ platform for computational target discovery. The company focuses on identifying novel drug targets and developing first-in-class therapeutics for immuno-oncology, with a pipeline that includes two key assets: COM902, an anti-TIGIT antibody in Phase 1 trials for advanced solid tumors, and COM701, an anti-PVRIG antibody in Phase 1/2 trials for recurrent ovarian cancer. COM902 is being evaluated both as monotherapy and in combination with COM701, targeting multiple malignancies including ovarian, lung, colon, and head and neck cancers. The Phase 1 study (NCT04354246) has completed enrollment with data expected to inform dose selection and potential expansion cohorts. Meanwhile, the Phase 1/2 trial for COM701 (NCT06888921) is actively recruiting patients with recurrent ovarian cancer, with completion anticipated in early 2027. With a strong computational platform and a pipeline addressing validated immune checkpoints, Compugen is positioned to capitalize on the growing immuno-oncology market. However, the company remains early-stage with no approved products, and success hinges on clinical data readouts and potential partnerships to advance its candidates through later-stage development.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 data for COM902 monotherapy and in combination with COM70160% success
• Q2 2027Interim safety/efficacy data from Phase 1/2 trial of COM701 in ovarian cancer55% success
• TBDPotential partnership or licensing deal for COM902 or COM70140% success